title: [Timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination in primary open-angle glaucoma or ocular hypertensive patients].
abstract: OBJECTIVE
  To establish the efficacy and safety of timolol 0.5%/dorzolamide 2% fixed combination versus timolol 0.5%/pilocarpine 2% fixed combination, each given twice daily, in primary open-angle glaucoma and ocular hypertensive patients.
  
  
  METHODS
  In this prospective, multicenter, double-masked trial, 37 patients were treated twice daily with timolol for 4 weeks. Then, they were randomized to one of the treatment medications for 6 weeks, after which they were treated with timolol again for 2 weeks before placed on the opposite treatment medication for 6 weeks.
  
  
  RESULTS
  A total of 36 patients completed the trial. The mean baseline intraocular pressure (IOP) was 22.3 +/- 3.7 mmHg. Following 6 weeks of treatment, the mean decrease of IOP was 18.0 +/- 2.2 mmHg for timolol/dorzolamide combination and 17.4 +/- 2.0 for timolol/pilocarpine combination. The mean diurnal curve IOP was 18.1 +/- 2.2 mmHg for timolol/dorzolamide group and 16.7 +/- 1.9 mmHg for timolol/pilocarpine group. These differences were statistically significant. Statistically more patients reported ocular pain and diminished vision during use of the timolol/pilocarpine combination.
  
  
  CONCLUSIONS
  This study suggest that timolol 0.5%/pilocarpine 2% fixed combination can provide at least similar efficacious reduction in IOP as timolol 0.5 %/dorzolamide 2% fixed combination in patients with primary open-angle glaucoma and ocular hypertension.
authors.affiliation: Kliniki Okulistyki Akademii Medycznej im. Ludwika Rydygiera w Bydgoszczy.
authors.forename: Jakub J
authors.initials: JJ
authors.lastname: Kałuzny
authors.forename: Jerzy
authors.initials: J
authors.lastname: Szaflik
authors.forename: Krystyna
authors.initials: K
authors.lastname: Czechowicz-Janicka
authors.forename: Józef
authors.initials: J
authors.lastname: Kałuzny
authors.forename: Alicja
authors.initials: A
authors.lastname: Orzałkiewicz
authors.forename: Anna
authors.initials: A
authors.lastname: Zaleska-Zmijewska
authors.forename: Małgorzata
authors.initials: M
authors.lastname: Krajewska
authors.forename: Jeanette A
authors.initials: JA
authors.lastname: Stewart
authors.forename: Jessica N
authors.initials: JN
authors.lastname: Leech
authors.forename: Wiliam C
authors.initials: WC
authors.lastname: Stewart
mesh_terms: D000319:Adrenergic beta-Antagonists / Q000627:therapeutic use; D000368:Aged; D000959:Antihypertensive Agents / Q000627:therapeutic use; D018592:Cross-Over Studies; D004311:Double-Blind Method; D004338:Drug Combinations; D005260:Female; D005902:Glaucoma, Open-Angle / Q000188:drug therapy*; D006801:Humans; D007429:Intraocular Pressure / Q000187:drug effects*; D008297:Male; D008875:Middle Aged; D008916:Miotics / Q000627:therapeutic use; D010862:Pilocarpine / Q000627:therapeutic use*; D013449:Sulfonamides / Q000627:therapeutic use*; D013876:Thiophenes / Q000627:therapeutic use*; D013999:Timolol / Q000627:therapeutic use*; D016896:Treatment Outcome
chemical_list: D000319:Adrenergic beta-Antagonists; D000959:Antihypertensive Agents; D004338:Drug Combinations; D008916:Miotics; D013449:Sulfonamides; D013876:Thiophenes; D010862:Pilocarpine; D013999:Timolol; C062765:dorzolamide